Vimarsana
Biggest News Aggregation in the World

Page 23 - Nuclear Export News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nuclear Export. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nuclear Export Today - Breaking & Trending Today

Menarini Industrie Farmaceutiche Riunite: Karyopharm and Menarini Group Announce Orphan Medicinal Product Designation from the European Commission for Selinexor for the Treatment of Myelofibrosis - Vimarsana News

Menarini Industrie Farmaceutiche Riunite: Karyopharm and Menarini Group Announce Orphan Medicinal Product Designation from the European Commission for Selinexor for the Treatment of Myelofibrosis

Published: November 1, 2022

NEWTON, Mass. and FLORENCE, Italy, Nov. 1, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, and

Source: finanznachrichten.de
Related Topics:
United StatesUnited KingdomNorthern IrelandSouth KoreaReshma RangwalaSelective Inhibitor Of Nuclear ExportMenarini GroupCommittee For Orphan Medicinal ProductsEuropean UnionHead Of Medical Affairs OncologyKaryopharm Therapeutics IncDrug AdministrationEuropean CommissionExchange CommissionPrnewswire Karyopharm Therapeutics IncNational Organization Of Rare DiseasesEuropean Medicines AgencyEuropean Economic AreaChief Medical OfficerOlivia Del PuertoMedical Affairs OncologyOrphan MedicinalNational OrganizationRare DiseasesNorthern European
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Vimarsana News

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Published: November 1, 2022

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that...

Source: prnewswire.com
Related Topics:
United KingdomSouth KoreaSelective Inhibitor Of Nuclear ExportPrnewswire Karyopharm Therapeutics IncKaryopharm Therapeutics IncStock Incentive PlanNasdaq Listing RuleSelective InhibitorNuclear ExportKaryopharm TherapeuticsKaryopharm Therapeutics Inc
Karyopharm and Menarini Group Announce Orphan Medicinal Product Designation from the European Commission for Selinexor for the Treatment of Myelofibrosis - Vimarsana News

Karyopharm and Menarini Group Announce Orphan Medicinal Product Designation from the European Commission for Selinexor for the Treatment of Myelofibrosis

Published: November 1, 2022

/PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, and the Menarini...

Source: prnewswire.com
Related Topics:
United StatesUnited KingdomNorthern IrelandSouth KoreaMenarini Industrie Farmaceutiche RiuniteReshma RangwalaSelective Inhibitor Of Nuclear ExportMenarini GroupCommittee For Orphan Medicinal ProductsEuropean UnionHead Of Medical Affairs OncologyKaryopharm Therapeutics IncDrug AdministrationEuropean CommissionExchange CommissionPrnewswire Karyopharm Therapeutics IncNational Organization Of Rare DiseasesEuropean Medicines AgencyEuropean Economic AreaChief Medical OfficerOlivia Del PuertoMedical Affairs OncologyOrphan MedicinalNational OrganizationRare Diseases
Karyopharm and Menarini Group Announce Orphan Medicinal Product Designation from the European Commission for Selinexor for the Treatment of Myelofibrosis - Vimarsana News

Karyopharm and Menarini Group Announce Orphan Medicinal Product Designation from the European Commission for Selinexor for the Treatment of Myelofibrosis

Published: October 31, 2022

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, and the Menarini Group...

Source: prnewswire.com
Related Topics:
United StatesUnited KingdomNorthern IrelandSouth KoreaReshma RangwalaSelective Inhibitor Of Nuclear ExportMenarini GroupCommittee For Orphan Medicinal ProductsEuropean UnionHead Of Medical Affairs OncologyKaryopharm Therapeutics IncDrug AdministrationEuropean CommissionExchange CommissionPrnewswire Karyopharm Therapeutics IncNational Organization Of Rare DiseasesEuropean Medicines AgencyEuropean Economic AreaChief Medical OfficerOlivia Del PuertoMedical Affairs OncologyOrphan MedicinalNational OrganizationRare DiseasesNorthern European
Karyopharm and Menarini Group Announce Orphan Medicinal Product Designation from the European Commission for Selinexor for the Treatment of Myelofibrosis - Vimarsana News

Karyopharm and Menarini Group Announce Orphan Medicinal Product Designation from the European Commission for Selinexor for the Treatment of Myelofibrosis

Published: October 31, 2022

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, and the Menarini Group...

Source: prnewswire.com
Related Topics:
United StatesUnited KingdomNorthern IrelandSouth KoreaReshma RangwalaSelective Inhibitor Of Nuclear ExportMenarini GroupCommittee For Orphan Medicinal ProductsEuropean UnionHead Of Medical Affairs OncologyKaryopharm Therapeutics IncDrug AdministrationEuropean CommissionExchange CommissionPrnewswire Karyopharm Therapeutics IncNational Organization Of Rare DiseasesEuropean Medicines AgencyEuropean Economic AreaChief Medical OfficerOlivia Del PuertoMedical Affairs OncologyOrphan MedicinalNational OrganizationRare DiseasesNorthern European